Gene editing revolutionizes medicine and cures Canadian teenager of chronic granulomatous disease
Ty Sperle, 18, is experiencing a moment that he considers surreal after being the first patient in the world to receive a cure for chronic granulomatous disease (CGD), a rare genetic condition. The innovative treatment, based on gene editing, marks a turning point in medicine, according to him.
For the young man, daily worries about infections, painful mouth ulcers and the medication routine disappeared. However, despite being “Participant 1” in a study published in the renowned New England Journal of Medicine that details the gene-editing procedure that resulted in a cure, the changes in his daily life were not drastic.
“I feel very similar to how I felt before,” the UBC Okanagan student revealed, describing his perception after treatment.
Sperle was diagnosed with CGD at age five. The disease seriously compromises the immune system, preventing white blood cells from producing an essential substance to fight bacteria and infections. This flaw makes the body extremely vulnerable, with patients facing a constant risk of severe infections.
“There was a huge gap in his natural defense,” explained Dr. Stuart Turvey, a pediatric immunologist at BC Children’s Hospital and Sperle’s doctor since childhood. “There was always a fear that bacteria could penetrate and cause an infection.”
Even with a preventive care regimen that included long-term antibiotics and antifungals, Sperle required several hospitalizations. A severe bacterial lung infection in early childhood led to the diagnosis of the disease, and an infection in the skull bones, in sixth grade, took about two years to control. For some individuals, infections can be lethal.
In recent years, bone marrow transplantation has become the main treatment for CGD, according to Dr. Turvey. However, for Sperle, this alternative was unfeasible due to the impossibility of finding a compatible donor.
The immunologist closely monitored advances in gene editing. So, when the company Prime Medicine, from the United States, announced a clinical trial at CHU Sainte-Justine, in Montreal, he promptly contacted Dr. Élie Haddad, a colleague and responsible for the study, presenting Sperle as an ideal candidate.
Dr Stuart Turvey’s leadership in genetic research
Sperle commented that the biggest difficulty in the entire process was the uncertainty inherent to the transplant.
“I was kind of nervous about it,” the teen said.
Despite already having knowledge about gene editing, he had no idea that the technology would be applied so quickly. However, trust in Dr. Turvey was crucial.
“He’s been my doctor for as long as I can remember,” Sperle said. “He’s a smart guy and knows what he’s talking about. And his confidence in healing helped me.”
There is a strong belief that gene editing is about to transform medicine. Fundamental research that seeks to identify and correct the genes that cause various diseases is beginning to be applied in clinical practice. Sperle’s case serves as a vital precedent, demonstrating the feasibility of the technique for genetic conditions previously without effective treatment, consolidating gene editing as a potent tool for future therapies.
Dr. Turvey detailed that Sperle’s blood stem cells were prepared and treated with a gene editing product. This product acted directly on the mutation in the gene responsible for CGD, correcting it. As a result, the patient’s white blood cells can now produce the chemical needed to fight infections.
Ty Sperle’s cure inspires hope that gene editing can be applied to treat other rare diseases, the doctor explained. Although genetic diseases individually are infrequent, collectively they account for approximately one-third of patients admitted to BC Children’s Hospital.
“No jurisdiction can do this alone,” he highlighted. “This work depends on collaboration between several research centers.”
Josie Osborne, British Columbia’s Minister of Health, said in a statement that Sperle’s trajectory highlights “the power of public health, research and global cooperation.”
“It is incredible to see a young man from British Columbia cured of a potentially fatal genetic disease thanks to the innovation of clinical teams,” she said. “This offers hope to families facing rare diseases and demonstrates how a smart investment in science can lead to life-changing care.”
Sperle revealed that he is not sure how to feel about such an innovative moment in medicine. He is currently in his second year at UBC, after taking time off last year to travel to Montreal and undergo treatment. After a few weeks of isolation, he returned to campus. Although he studies science, he is considering switching to engineering. He continues to take care of his health, but notes that this year doesn’t look much different than the last.
“It’s really crazy to think about,” Sperle concluded. “We’re definitely at a turning point in medicine, and being cured through gene editing is incredible. But I’m not sure what to say.”
